Cytotoxic T lymphocyte (CTL) activation requires specific T cell receptor (TCR)-class I major histocompatibility complex (MHC) antigen complex interactions as well as the participation of coreceptor or accessory molecules on the surface of CTL. CD8 can serve as a coreceptot in that it binds to the same MHC class I molecules as the TCR to facilitate efficient TCR signaling. In addition, CD8 can be "activated" by TCR stimulation to bind to class I molecules with high avidity, including class I not recognized by the TCP, as antigenic complexes (nonantigen [Ag] class I), to augment CTL responses and thus serve an accessory molecule function. A Glu/Asp227--+Lys substitution in the class I cx3 domain acidic loop abrogates lysis of target cells expressing these mutant molecules by alloreactive CD8-dependent CTL. Lack of response is attributed to the destruction of the CD8 binding site in the 0~3 domain which is likely to disrupt CD8 coreceptor function. The relative importance of the class I e~3 domain acidic loop Glu227 in coreceptor as opposed to accessory functions of CD8 is unclear. To address this issue, we examined CTL adhesion and degranulation in response to immobilized class I-peptide complexes formed in vitro from antigenic peptides and purified class I molecules containing wild-type or G1u227--+Lys substituted oL3 domains. The 0¢3 domain mutant class I-peptide complexes were bound by CTL and triggered degranulation, however to much lower levels than wild-type class I-peptide complexes. In further experiments, it is directly demonstrated that the 0~3 domain mutant class I molecules, which lack the Glu227 CD8 binding site, still serve as TC1L-activated, avidity-enhanced CD8 accessory ligands. However, mutant class I-peptide Ag complexes failed to effectively serve as CD8 coreceptor ligands to initiate TCR-dependent signals required to induce avidity-enhanced CD8 binding to coimmobilized non-Ag class I molecules. Thus the Glu227--+Lys mutation effectively distinguishes CD8 coreceptor and avidityenhanced CD8 accessory functions.
C
Ytotoxic T lymphocyte activation is a process that involves multiple cell surface protein interactions with antigen-bearing target cells and a cascade of signal transduction events which lead to proliferation and effector functions (1, 2) . T cell receptor interaction with MHC class I molecules bound with antigenic peptides on target cells is responsible for the specificity of CD8 + CTL recognition. So-called coreceptors and accessory molecules on the surface of CTL interact with their respective ligands on target cells and also contribute to T cell activation by increasing the avidity between CTL and targets, amplifying TCR-initiated signals, transducing distinct signals, or a combination of these mechanisms (1, 2) . The CD8 molecule is typically expressed as a disulfidelinked ot/[3 heterodimer on the mature murine CD8 + T cell subset and plays a critical role in CD8-dependent CTL recognition and activation (3) . In CTL recognition, CD8 can function as a coreceptor by binding to the same MHC class I molecules as the TCR (3) (4) (5) , as well as an accessory molecule by binding to any class I molecules, including those which do not interact with the TCIL (non-Ag class I) (6) (7) (8) (9) (10) . The relative importance of CD8 coreceptor or accessory interactions with class I molecules toward T cell activation may depend on the density of specific MHC class I-peptide complexes on the target cells as well as the affÉnity of the interaction between the MHC-peptide complexes and the TC1K (9, 11, 12) . When the TC1K is triggered, signals are generated which activate CD8 to a state of higher avidity, and consequently, the "activated," avidity-enhanced CD8 binds MHC class I molecules and facilitates CTL activation either by strengthening the interactions between CTL receptors and their ligands, or transducing additional signals for T cell activation (6) (7) (8) (9) (10) .
It has been shown by site-directed mutagenesis that the negatively charged loop (residues 222-229) in the highly conserved e~3 domain of MHC class I molecules plays an important role in CD8-dependent CTL recognition and activation (4, (13) (14) (15) . For instance, the Glu227--+Lys substitution in the D d c¢3 domain abrogates the CD8-dependent, alloreactive CTL killing of target cells expressing these mutant molecules (4, 13, 14) . The inability ofmurine CD8-dependent CTL to lyse targets bearing the e¢3 mutated class I molecules was attributed to the disruption of CD8 interaction with class I (13) (14) (15) . Consistent with these results, mutational analysis and adhesion assays using CD8ot-transfected Chinese hamster ovary cells, demonstrate that the acidic loop in (x3 domain of HLA class I molecules is a binding site for human CD8o~/ot homodimers (15) . The site(s) on the MHC class I molecules that participate in high avidity TCR-activated CD8 binding has not been identified. Whether the (x3 domain acidic loop is essential for TCR-activated CD8ot/[3 heterodimer binding to class I is unknown. That mutations in the c~2 domain of HLA class I molecules can also interfere with CD8odot binding suggest the possibility that other sites in addition to the c~3 domain on class I may be involved in CD8 interaction(s) (16, 17) , perhaps including activated CD8 binding.
Using immobilized purified chimeric class I molecules consisting of Db0~10L2 or Kbodot2 and Ddo~3 domains, in which the DdoL3 domain is either the wild-type or the mutant with a Glu227--~Lys substitution, the role of Glu227 in the or3 domain acidic loop of class I in CD8 coreceptor and TCR-triggered avidity-enhanced CD8 accessory functions of cloned CTL was assessed. The mutant class ! effectively serves as an activated CD8 accessory ligand, indicating that Glu227 is not required for this type of CD8 interaction. In contrast, the purified mutant class I molecules were unable to effectively coengage TCR and CD8 to initiate TCRdependent activation events.
Materials and Methods

mAbs.
A murine hybridoma that secretes an IgG2 a mAb recognizing H-2 D b molecules, B22.249 (18) , was a gift from Dr. U. Hammerling (Memorial Sloan-Kettering Cancer Center, New York). The Kb-specific mAb, Y3 (IgG2b) (19) , and Dd-specific mAbs, 34-5-8s (IgG2a) (20) and 34-2-12s (IgG2~) (20) were produced from their respective hybridomas obtained from American Type Culture Collection (ATCC; Rockville, MD). The rat antimouse CD8-producing hybridoma, 2.43 (IgG2b) (21) was obtained from ATCC, and the YTS169.4 mAb (rat IgG2b) (22) was purchased from Cedarlane Laboratories (Hornby, Ontario, Canada). The hamster anti-mouse TC1Kc(/[3 mAb, H57-597 (23), was purchased from Pharmingen (San Diego, CA). Type or Mutant oe3 Domains. M12 (H-2a) , a B lymphoma cell line, was transfected with chimeric class I genes as described (13, 24, 25) . Exon shuffled genes consisting of the oL1 and or2 domain of the H-2 D b or K b genes and either the wild-type or Glu227---->Lys substituted o~3 domain of the H-2 D a (13) were transfected into the M12 cell line by electroporation, and are referred to herein as M12.Db/Dawt, M12.Db/DaLys, M12.KB/Dawt, and M12.Kb/ DaLys, respectively.
Transfectant Cell Lines Expressing Chimeric H-2 Class I with Wild-
Cloned CTLs. Clone 3/4 is specific for H-2 D b and the influenza nucleoprotein (NP) 1 (365-380) of A/PlK/8/34 influenza virus and was maintained as described previously (7) . The NP peptide used in this study is a 10-mer (NP366-374) with a tyrosine at the NH 2 terminus (Y-ASNENMETM) that was synthesized and purified at Multiple Peptide Systems (San Diego, CA). The Kb-allospecific CTL clone, 11, was described previously (26, 27) .
Purification of Chimeric Murine MHC Class I Molecules Bearing Wild-Type or Mutant ex3 Domains. The chimeric H-2 class I molecules, Db/Ddwt, Db/DdLys, Kb/Dawt, and Kb/DdLys were purified from 0.5-1.0 X 10 l° transfectant cells by immunoafflnity chromatography as described (27, 28) with modifications. B22.249 (D b o.1; 29) and Y3 (K b el2; 30) mAb columns were used for immunoaffinity purification of DB/D a and KB/D a chimeric molecules, respectively. To avoid cross contamination, separate columns were used for the wild-type and the mutant class I molecules. Detergent lysates of the transfectant cells were passed over the B22.249 or Y3 columns. Columns were washed with 0.1% deoxy cholate (DOC), 40 mM NaC1, 10 mNl Tris, pH 8.2, and 0.5% DOC, 0.65 M NaC1, 10 mM Tris, pH 8.5. The chimeric molecules were then eluted from the columns using 0.5% DOC, 0.15 M NaC1, 15 mM Na2CO 3, pH 10.5 (27) . Solid-phase ELISA of purified class I chimeric molecules was performed with various mAbs as described previously (28) . Peak fractions showing strong ELISA reactivities were pooled and used as described (27, 28) . Protein quantitation was determined by Micro-BCA assay (Pierce Chemical Co., Rockford, IL). Other immunoaffinity-purified H-2 class I used in this study, including K b and D b isolated from EL4 cells and K k isolated from 1KDM-4, as well as I-E a class II molecules isolated from A20.Cy, were purified as described previously (28, 31) .
Assays for CTL Binding and Degranulation. CTL degranulation was assessed by measuring the serine esterase (SE) activity released into the medium with the N'-benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT) assay as described (32) . Stimulator cells were pulsed with the NP peptide for 30 min at 1KT, washed three times with 2% FCS-RPMI, and 3 X 105 stimulator cells were incubated with 105 cloned CTL for 4 h. 20 ~1 ofsupematant was recovered and the BLT reactions proceeded for 20 min, whereupon the ODa0sn m was determined. SE release is calculated as AOD405 ..... = OD40s .... (CTL + stimulators) -OD40snm(CTL alone).
CTL adhesion and degranulation responses to purified class I and coimmobilized proteins have been described previously in detail (7, 27, 32) . In experiments involving peptide pulsing of purified class I molecules, the class I-bearing wells were incubated with NP peptide resuspended in 2% FCS-PBS at 37°C for 16 h to form peptide-antigen complexes as previously described (7, 32) . Either 1 or 2 × 105 51Cr-labeled CTL were incubated for 4 h at 37°C on protein-bearing plate wells, and unbound cells were then removed. In experiments using fluid phase anti-TCR-o~/[3 mAb, the antibody was added to CTL in suspension and the cells immediately placed into class I-bearing wells. Cell binding was calculated as: percent specific cell bound = 100 × [(cpm bound)/ (total cpm-spontaneous cpm)]. Degranulation by CTL was determined simultaneously with CTL binding from the same wells. SE release is expressed as AOD405 .... = OD40snm(CTL + immobilized class I) -OD40snm(CTL + wells blocked with 2% FCS in PBS). All determinations were done in triplicate for each condition unless specified.
CytotoxicityAssay. Target cells were labeled with SlCr and then pulsed with NP peptide at the concentrations indicated. After washing, 104 target cells were incubated with the CD8-dependent, NP-specific CTL clone 3/4 at a 5:1 E/T ratio for 5 h in V-bottom microtiter plates in triplicate. Percent specific SlCr release was calculated as: [(experimental release -spontaneous release)/(maximum release -spontaneous release)] × 100. Results are expressed as mean percent specific SlCr release. In all experiments, the spontaneous 51Cr release was <7.5% of the total.
Anti-CD8 mAb-Blocking Experiments. For anti-CD8 mAb-blocking experiments, the cloned CTL were incubated with the indicated CD8-specific antibodies at room temperature for 30 rain before carrying out the assays. Anti-CD8 mAb, 2.43 was used at dilution 1:4 of the culture supematant and purified YTS169.4 was used at 5 Ixg/ml. (4, 13-15, 24, 33) . The inabihty or reduced ability of CDS-dependent CTL to lyse these targets was attributed to failure of CD8 to bind the mutated MHC class I molecules on the target cells. In the present study, we examined the ability of an H-2 Db-restricted, influenza NP~pecific CTL, clone 3/4, to lyse, or degranulate in response to, target cells transfected with a chimeric cDNA encoding the D b odlx2 domain and D a o~3 domain. The D a o~3 domain is either the wild-type or mutant with a Glu227--)Lys substitution (13, 24, 25) . Both the transfectants, M12.Db/Dawt or M12.Db/D%ys, express comparable levels of the hybrid D b molecules as detected by FACS ® analysis using a Db-specific mAb, B22.249 (data not shown). The target cells were pulsed with NP peptide at different concentrations, and cytolysis was measured by 51Cr release. As expected, and similar to our previous report (24) , M12.Db/Dawt target cells were killed by clone 3/4 to a level comparable to EL4 (H-2b), which expresses natural D b molecules (Fig. 1 A) Peptide Concentration (-LogM) to M12.Db/Dawt lysis ( Fig. 1 A) . First, the maximal levels of lysis of M12.Db/D%ys (20%) were only one-third to one-half of that of M12.Db/Ddwt (40-50%). Second, the concentration of peptide required to obtain significant lysis was >100-fold higher in M12.Db/D%ys than in M12.DU/ Dawt. These results are consistent with our previous report in which lysis by a Kb-restricted, OVA-specific CTL clone of M12 cells transfected with Kb/D%ys gene was substantially lower and required higher concentrations of OVA .Db/DdLys (C') cells were also determined. Clone 3/4 cells were incubated with anti-CD8 antibodies at room temperature for 30 n'fin before incubating with the peptide-pulsed transfectant cells. Anti-CD8 mAb, 2.43, was used at 1:4 dilution of culture supernatant, and YTS169.4 used at the concentration of 5 p~g/ml. In all the panels, SE release is expressed as the mean of triplicate wells and variation is < 10% of the mean.
Results
Antigen
peptide than target cells transfected with the KU/Ddwt gene (24) . M12.Db/Ddwt cell lysis by clone 3/4 CTL was almost completely blocked by CD8oL-specific mAbs 2.43 and YTS169.4 at lower peptide concentrations, while partially inhibited when peptide concentrations were high ( Fig. 1 B) . This confirmed that the clone 3/4 killing is CD8 dependent, and also showed that CD8 dependency is related to the numbers of MHC class I-peptide complexes involved in the CTL-target interactions (11, 12) . Interestingly, even the cytolysis of M12.Db/DdLys was partially blockable by anti-CD8 mAbs ( Fig. 1 C) suggesting that CD8 may still participate to some extent in CTL recognition of mutant class I-peptide complexes. Similar to the cy- (7, 27, 32) . Since B22.249 mAb recognizes an or1 domain epitope of D b, independent of the o~3 domain (29) , it was used for immunoaffinity purifications of Db/Ddwt and Db/ D%ys chimeric molecules. The purified Db/Ddwt (pDb/ Ddwt) and Db/DdLys (pDb/D%ys) were analyzed using solidphase ELISA (28) ( Table 1) . Both pDb/Ddwt and pDb/DdLys were strongly positive for the B22.249 (D b od) epitope; while negative for the 34-5-8s epitope (D d clloL2). As expected, the pDb/Ddwt, but not the pDb/DdLys, was reactive with 34-2-12s (D d o~3) since the D d Glu227-+Lys substitution abrogates recognition by 34-2-12s (13, 14) . All preparations were standardized by protein and ELISA assays.
The pDb/Dawt, pDb/DdLys, and pD b (isolated from EL4 cells) were immobilized separately on microtiter plate wells, pulsed with NP peptide at the concentrations indicated, and tested for their abilities to trigger H-2 Db-restricted, NP-specific CTL (Fig. 3) . As we have shown previously (7, 32) , the NP-specific CTL clone 3/4 bound, and degranulated in response to, the immobilized pDb-Np peptide complexes (Fig. 3) . Clone 3/4 cells also bound to both pDb/Ddwt and pDb/DdLys, but the levels of binding and response are dramatically different (Fig. 3 A) . We consistently observed that the maximal percentage of clone 3/4 CTL cells adhered to immobilized pDb/Ddwt was more than threefold greater than to pDb/D%ys (38% compared with 10%). CTL binding to both pDb/Dawt and pDb/ DdLys was peptide dose dependent and reached plateau at 10 laM NP peptide, which probably represents a peptide concentration resulting in saturation of peptide binding by the immobilized class I molecules. CTL SE release response showed very similar results (Fig. 3 B) , and was also peptide dose dependent with maximal degranulation a minimum of three to five times stronger to pDb/Dawt than pDb/D%ys.
The pDb/Ddwt and pDb/DdLys density dependence for CTL binding and degranulation was also investigated (Fig. 4) . Both pDb/Ddwt and pDb/DdLys were coated separately at several densities and pulsed with a saturating concentration of NP peptide. CTL adhesion (Fig. 4 A) and degranulation response (Fig. 4 B) was density dependent for pDb/Ddwt and pDb/DdLys, with pDb/Ddwt supporting a threefold greater maximal CTL binding (Fig. 4 A) and triggering a fivefold stronger maximal degranulation response (Fig. 4 B) than pDb/DdLys. When a saturating amount ofpeptide was used to pulse both the pDb/Ddwt and pDb/DdLys at or below saturating densities (0.025 lag/well or less), 8-16-fold more pDb/D%ys molecules were required to reach the same level of CTL binding to pDb/Dawt pulsed with peptide (Fig. 4 A) . About a 10-fold higher density of pDb/DaLys was needed to induce a similar level of clone 3/4 SE release as needed for pDb/Ddwt, with saturating peptide (Fig. 4 B) . An ELISA of immobilized pDb/Ddwt and pDb/DaLys done in parallel using Db-specific mAb, B22.249, confirmed that at the same input of purified class I protein, the immunoreactive D b epitopes for both pDb/Dawt and pDb/D%ys were at comparable density (Fig. 4 C) . Clone 3/4 adhesion (Fig. 5, A and B) and SE release (Fig. 5, C and D) to both NP-pulsed pDb/Ddwt and pDb/D%ys were significantly inhibited by anti-CD8 mAb, 2.43 and YTS169.4, suggesting that not only the pDb/Ddwt, but also the low level pDb/D%ys-triggered responses are CD8 dependent, thus the pDb/DdLys may still interact to some extent with CD8 molecules despite the Glu 227-->Lys substitution in the ix3 domain.
In summary, these results indicate that the Glu227--)Lys mutation in the cx3 domain of class I raises the threshold of class I density required for CDS-dependent Ag-specific CTL binding and response severalfold, and substantially lowers the maximal response achieved. This provides the first direct quantitative comparison of the ability of wildtype and el3 mutant class I molecules to serve as Ag-presenting molecules, since it excludes the potential participation of both defined and undefined non-class I accessory molecule interactions.
Both the pDb /Dawt and pD~ /DaLys Serve as Effective Ligands
for TCR-ttiggered CD8 Adhesion and CTL Response. CD8 can function both as a "coreceptor" and as an "accessory molecule" during CTL recognition (5) (6) (7) (8) (9) (10) 24) . Evidence suggests that when TCR is triggered, signals are generated which activate CD8 to a state of higher avidity, and consequently, the activated avidity-enhanced CD8 binds MHC class I molecules and facilitates CTL activation (6-10). For instance, soluble Ab to TCR alone is not a sufficient stimulus for CTL degranulation, however it can trigger avidityenhanced CD8 accessory-type binding to non-Ag class I and cosignaling function, resulting in CTL degranulation (6-8). As shown above, the Db/DaLys mutant class I could not effectively activate CTL. One possibility that could contribute to this result would be that the Db/D%ys molecule does not serve as an effective ligand for TCR-activated CD8 as compared to Db/Dawt molecules. To test this possibility, we stimulated the Kb-specific CTL clone 11 with soluble anti-TCIk mAb (H57.597), and determined whether the CTL bind to immobilized pDb/Ddwt or pDb/ D%ys, non-Ag class I molecules in this system (6) (7) (8) . Clone 11 triggered by fluid-phase anti-TC1K-ci/[3 bound substantially to both pDb/Ddwt and pDb/DdLys in a density-dependent manner (Fig. 6 A) , but not to the purified murine class II molecule, I-E d (data not shown). We also compared the ability of the pDb/Dawt and pDb/DaLys molecules to provide CD8-dependent cosignals for CTL degranulation in conjunction with soluble anti-TCR antibody. Both pDb/Dawt and pDb/DaLys were found to efficiently activate CTL degranulation response in conjunction with a low concentration of soluble anti-TCP, mAb that is otherwise insufficient to stimulate degranulation (Fig. 6 B) . The soluble anti-TCP,-o~/[~ triggered CTL binding and degranulation to pDb/DdLys is comparable to or slightly lower (70-90%) than that ofpDb/Dawt throughout the immobilized class I MHC density curves (Fig. 6 , A and B, data not shown). Both binding and SE release of clone 11 in response to either pDb/Ddwt or pDB/DdLys non-Ag class I molecules was blockable by an anti-CD8 mAb, 2.43 ( Fig. 6 , A and /3), indicating that the soluble TCP,. mAb triggered CTL binding to the immobilized class I molecules and observed SE release is mediated by CD8 in an accessory-type interaction. The Kb/Ddwt and Kb/DdLys class I molecules were also purified and tested for their ability to serve as TCtL-triggered, avidity-enhanced CD8 ligands for adhesion and response, and yielded similar results to the Db/Ddwt and Db/DdLys (data not shown).
We have demonstrated previously that a suboptimal CTL adhesion and response to specific Ag class I can be augmented when non-Ag class I is coimmobilized (7, 27) . Augmentation of adhesion and degranulation by the non-Ag class I was shown to be mediated by CD8 in an accessory as opposed to coreceptor capacity (7, 27) . We examined whether pDB/Ddwt or pDb/DaLys can serve as non-Ag CD8 accessory ligands to enhance CTL binding and degranulation. Both pDb/Dawt and pDB/DdLys were titrated and coimmobilized with a suboptimal density of purified K b alloantigen on the wells. The binding and SE release of the K b allo-specific clone 11 in response to suboptimal K b and coimmobilized pDB/Ddwt or pDB/DdLys were determined (Fig. 7) . Augmentation of clone 11 binding (Fig. 7 A) and triggering of degranulation (Fig. 7 B) facilitated by the coimmobilized pDb/Dawt or pDB/DdLys was to very similar levels throughout the class I density curves. As expected, the enhanced binding and augmented SE release facilitated by both pDb/Dawt and pDb/DaLys were mediated by CDt, as anti-CD8 mAbs significantly blocked clone 11 binding and response (Fig. 7, A and B) . We also found that the coimmobilized pKb/Ddwt or pKb/DdLys molecules are equally effective as avidity-enhanced CD8 ligands to enhance CTL binding and degranulation when the Db-restricted, NP-specific CTL clone 3/4 is triggered by suboptimal Db-Np peptide complexes (data not shown). Taken together, these results show that the Glu227-gLys substitution in the c~3 domain of class I molecules does not abrogate the ability of class I to serve as a ligand for activated CD8 accessory interactions. This indicates that the Glu227 in murine class I molecules is not required for TCP,-triggered CD8 binding. Since the class I o~3 domain mutants can still effectively serve as avidity-enhanced CD8 ligands, the poor ability of pDb/DdLys to trigger CTL adhesion and degranulation response is not explained by an inability to bind to CD8 per se.
The a3 Glu227-+Lys Substituted H-2 Class I-Peptide Complexes Are Defective in Initiating TCR Signals for Avidityenhanced CD8 Binding to Non-Ag Class I and CTL Response.
Since the DU/DdLys molecules can serve as effective non-Ag class I ligands for TCR.-activated, avidity-enhanced CD8 (Figs. 6 and 7) , we investigated whether Db/DdLyspeptide complexes are defective in initiating TCR. signals for avidity-enhanced, CD8-dependent CTL adhesion and response. We and others have shown that a suboptimal density of class I or soluble anti-TCR, mAb, which is not sufficient to fully activate CTL, can initiate TCR. signaling which in turn enhances CD8 binding to non-Ag MHC class I and augments CTL adhesion and responses (6, 7, 9, 10) . To test their effectiveness in initiating early TCR.-dependent events in T cell activation, both the pDb/Ddwt and pDb/DdLys were titrated and coated on plastic with or without coimmobilization of a non-Ag class I molecule, K k. After pulsing the immobilized class I with NP peptide, clone 3/4 CTL were added to the wells and their enhanced binding and SE release to coimmobilized non-Ag class I were determined (Fig. 8) . Coimmobilized K k greatly augmented clone 3/4 adhesion (Fig. 8 A) and SE release (Fig.  8 B) in response to pDb/Dawt-NP complexes. This effect was observed at the pDb/Ddwt input as low as 0.0008 Ixg/ well for enhanced binding (Fig. 8 A) , and 0.006 Ixg/well for augmented degranulation (Fig. 8 B) , while at these concentrations, pDb/Dawt alone does not trigger CTL adhesion or degranulation response. In contrast, over a range up to 0.05 Ixg/well input (approaching immobilization saturation), pDb/DdLys did not trigger CTL for enhanced bind- ing or SE release when coimmobilized with K k (Fig. 8, A and B). These results indicate that the o~3 domain mutation in MHC class I molecules likely affects initial low avidity or basal CD8 binding to class I-peptide Ag complexes which interferes with its CD8 coreceptor function, but not subsequent avidity-enhanced CD8 binding and accessory function.
Discussion
In the present report, we describe the direct comparison of wild-type MHC class I molecules with those bearing a Glu227-+Lys or3 domain mutation previously shown to substantially diminish or abrogate CD8-dependent CTL lysis (4, 13, 14, 24) , in mediating As-specific, CD8-dependent CTL clone adhesion and response. This was explored with their respective or3 mutant counterparts appear identical, suggesting that the point mutation in the ¢x3 domain does not affect peptide binding (24, 34) , despite the observation that the Asp227--+Lys substitution in another class I, L a, diminishes the interaction of this class I molecule with the endoplasmic reticulum peptide transporter, TAP, during biosynthesis (35) . We found the maximal CTL adhesion and degranulation response to be at least threefold greater to immobilized purified wild-type as opposed to mutant class F-presenting molecules pulsed with peptide. The mutant class I molecules did not achieve >10% of input CTL binding, which was only observed at high concentrations of antigenic peptide. These results are consistent with the differences in target cell lysis and degranulation responses we found with the same CTL clone in response to wild-type and mutant class I-bearing target cells. In experiments not easily approached using target cells, we show that in the presence of saturating peptide antigen, it requires an 8-16-fold higher density of immobilized mutant class I molecules to achieve the same level of CTL adhesion and response as with molecules bearing a wild-type o~3 domain. Surprisingly, we observed CTL avidity-enhanced CD8 binding induced by soluble anti-TCR mAb or alloantigen not only to class I bearing a wild-type o¢3 domain but also to class I 0~3 mutants which lack a critical CD8 binding site. Furthermore, additional signaling associated with avidity-enhanced CD8 binding was only modestly reduced or undiminished with the oL3 domain mutant class I relative to wild-type molecules in the two experimental systems used. In contrast, when incubated with peptide antigen, the mutant class I molecules were unable to trigger TCR-dependent signals necessary for the induction of avidity-enhanced CD8 binding to coimmobihzed non-antigen class I.
Several amino acid substitutions in the acidic loop of the conserved cx3 domain of class I disrupt CD8-dependent CTL antigen recognition (4, (13) (14) (15) 33) . This is likely to be due to interference with CD8 coreceptor function since the mutagenesis of the antigen-presenting class I, the ligand for the TCR, blocks response despite the presence of non-Ag class I on the same cell membrane, which in theory could serve as accessory ligands for CD8. More direct evidence for CD8 serving a coreceptor adhesive role has been provided recently by Luescher et al. (10) who examined CTL interactions with soluble wild-type and or3 mutant K a class I molecules. Using photoaffinity labeling techniques they directly demonstrated that CD8 can serve as a coreceptor by significantly strengthening cell surface TCR binding to soluble K d on an allo-specific CTL clone and this interaction was shown to be inhibited by a Lys substitution for the Asp227 in K d. However, there was no analysis of functional responses possible in this system to determine the relationship of binding to response, since class I in soluble monomeric form is not a stimulus for T cell responses. Our studies with solid phase class I provide a quantitative comparison of class I molecules bearing wild-type or the 013 domain mutation for CTL adhesion and response. Our data are consistent with and strengthen the conclusions of previous reports suggesting that the Glu227 mutation disrupts CD8 coreceptor interactions, as our results reveal that CD8 coreceptor engagement with peptide antigen-class I complexes is necessary for the TCR-dependent expression of avidity-enhanced CD8 binding to non-Ag class I and CD8 accessory function by CTL.
Binding and response to class I-bearing cells or surfaces by CTL appears to be a dynamic multistep process controlled by the TCR (8) . For example, no detectable CTL binding is observed to immobilized non-Ag class I in the absence of a TCR stimulus (6, 7) , thus CD8 interaction with class I is likely to be minimal in the absence of TCR triggering. However, if the TCR is engaged with immobilized specific antigenic class I, high avidity CD8 accessory interaction with coimmobilized non-Ag class I is observed and this results in the delivery of additional signals leading to phosphatidylinositol hydrolysis and degranulation of CTL (6, 7, 36) . That this process is likely to be sequential is supported by the observation that pretreatment of CTL with low concentrations of soluble antibodies to the TCR used to mimic antigen recognition, triggers subsequent high avidity CD8 binding to class I (6, 7) . The CD8 avidity enhancement is blocked by inhibitors of tyrosine phosphorylation suggesting that this process is dependent on intracellular signaling (6, 36) . Since the oL3 domain mutant class I is defective in supporting appropriate triggering through the TCR for CD8 binding in the presence of an excess of coimmobilized non-Ag class I (Fig. 8) , our results suggest a sequential model of CD8 receptor functions. In this model, the Glu227 of H-2 class I is essential for early low avidity CD8 coreceptor function in stabilizing TCR engagement with class I and facilitating initial TCR activation signals, but not for subsequent avidity-enhanced CD8 accessory molecule recognition and function which may involve additional binding sites on class I molecules. We do not exclude the possibility that when CD8 undergoes avidity enhancement it may also augment CD8 coreceptor function, but the expression of activated CD8 binding, regardless of whether the class I ligand is presenting the peptide antigen or not, would still be dependent on initial low avidity CD8 interactions.
It has been difficult to determine the relative contributions of CD8 coreceptor and accessory functions to CTL activation. However, since mutagenesis of the ci3 domain of the specific Ag-presenting class I molecule (potential CD8 coreceptor ligand) can ablate CD8-dependent CTL reactivity even in the presence of endogenous non-Ag class I (potential CD8 accessory ligand), it has been suggested that CD8 functions much more efficiently as a coreceptor than an accessory molecule (15, 24) . Results in the present report indicate that this simple interpretation can be significantly revised and clarified. Our data support the conclusion that the induction and expression of avidity-enhanced CD8 accessory function is simply dependent on an initial CD8 coreceptor priming function and CD8 accessory interactions can be critical for CTL responsiveness at low antigen density. Thus both CD8 coreceptor and accessory functions are important for CTL activation. Without the initiating TCR-dependent CD8 coreceptor activity which is prevented or greatly diminished by the Glu227--+Lys mutation, however, no avidity enhancement of CD8 occurs in response to or3 mutant class I-peptide antigen complexes and no subsequent CD8 accessory function can be observed. Therefore, our results provide an explanation for why little or no response is observed when peptide antigen is presented by the or3 domain mutant class I, despite the presence of non-Ag class I that in principle might be expected to compensate as CD8 accessory ligands for deficiencies in the o~3 mutated class I presenting molecules.
Interestingly, we found that the o~3 domain mutant class I molecule is still an effective ligand for avidity-enhanced CD8 binding, however it is unclear at present how CD8 binds the mutant molecules. This is hampered by the lack of understanding regarding how the avidity of CD8 is modulated by TCR triggering. It is clear from cell transfection and adhesion assays that the conserved or3 domain residues 222-229 acidic loop that includes Glu/Asp227 is a binding site on class I for CD8o~ homodimers when CD8ot is overexpressed (15) . Independent confirmation of an or3 binding site for CD8ot was provided by Fayen et al. (37) who showed that the human CD8ot IgV domain and the or3 domain of HLA-A2.1 can interact in soluble and immobilized forms and thus these domains of CD8 and class I, respectively, are sufficient for binding in vitro. It is possible that avidity-enhanced CD8 binding to mutant class I is still to the acidic loop of class I or3 domain, however its binding may be less dependent than CD8 in its low avidity state on the presence of Glu227. We have reported previously that avidity-enhanced CD8 binding is diminished by agents that inhibit cytoskeletal modifications (38). A consequence of cytoskeletal changes in response to TCR triggering may be an increase in cell spreading resulting in an increased surface area of contact. By increasing the area of contact, CTL would increase the quantity of CD8 that might engage class I on a target cell surface or on solid phase and the increased number of interactions of CD8 with class I between the two surfaces may be sufficient to support stable binding. A second consequence of cytoskeletal rearrangements induced by TCR triggering may be CD8 microclustering as found with the C3bi receptor (39) , increasing the multivalency of CD8 and in turn increasing the avidity but not necessarily the affinity of CD8 for class I. In both of these scenarios, avidity increases between the CD8 and class I-bearing surfaces may compensate for reductions in CD8 affinity from the Glu227-->Lys mutation without a change in CD8 binding site on class I.
It has recently been reported by Sun et al. (17) using transfection and overexpression systems that substitutions in the cx2 domain of HLA class I can disrupt cell-cell adhesion mediated by human CD80~/ot, suggesting that CD8 may have additional contact or binding sites on class I outside the or3 domain. Furthermore, recent studies using exon shuffling of domains between human and mouse class I genes, have provided evidence to suggest that the cx2 domain is likely to influence CD8 interactions with class I in T cell development and mature CD8 + T cell reactivity (40, 41) . Although additional CD8 binding sites on class I may be involved in basal or low avidity CD8 binding, CD8 interaction with these additional sites may be enhanced upon TCR triggering and support activated CD8 binding despite the Glu227-+Lys mutation.
The preceding discussion has not considered structural changes of CD8 that may result from TCR triggering. It is conceivable that the CD8 heterodimer undergoes a conformational change resulting from TCR-triggered intracellular signals, which enhance CD8 affinity for the or3 acidic loop or alternatively allows CD8 to bind additional sites on class I. This may provide an explanation for our observation of activated CD8 adhesion to the mutant molecules. In this context, Meyerson et al. (42) have found that the presence of the membrane proximal connecting peptide or stalk of CD8 reduces NH2-terminal CD8ot IgV domain binding to the cx3 domain and the binding of purified CD8ot in soluble form to class I is temperature sensitive.
These results could suggest that a specific or preferred conformation of CD8 or class I may be necessary for binding. Perhaps TCR-triggered changes in CTL lead to the induction or stabilization of appropriate CD8 conformation(s) for class I binding. In contrast to the report of Meyerson et al. and others involving CD8ot/oL homodimers, our study examines class I adhesion by CD8ot/[3 heterodimers which are typically expressed on mature murine CD8 + T cells. Expression or lack thereof, of the CD8 13 chain has been shown to substantially influence T cell thymic maturation (43-45) and CD8 13 undergoes structural changes depending on T cell differentiation and activation state (46) . It is less clear whether the CD8 13 chain directly participates in mature T cell recognition of class I (47-49), however it remains to be determined whether the CD8 13 chain may influence or possibly regulate basal or avidityenhanced CD8 binding to class I.
We show that the purified Glu227-->Lys oL3 mutant molecules bound with peptide antigen are very poor ligands for CTL adhesion and response, yet there is still some low level CTL reactivity to these mutant class I-antigen complexes. It is not clear how the CD8-dependent CTL clone is responding to the mutant class I molecules, but responses are only found at relatively high concentrations of peptide and this is also true for peptide-pulsed target cells ( Fig. 1  and 2; 24) . The CTL responses to the mutant class I complexes on cells and solid phase however were partially or completely inhibited by CD8-specific antibodies, suggestins that CD8 is still participating in mutant class I molecule recognition. The combination of multiple low affinity TCR and residual low avidity CD8 interactions may be sufficient to support the low level binding and response observed with the mutant class I presenting molecules and peptide. Alternatively or additionally, at high mutant class I-antigen complex density there may be some minimal TCR-dependent signaling resulting in a small degree of avidity enhancement of CD8 binding, but if this occurs it is inefficient, since we only observe a low level of CTL binding and response.
The induction of avidity-enhanced CD8 binding requires tyrosine phosphorylation but not downstream signaling events such as phosphatidylinositol hydrolysis (6, 36) . The specific intracellular signaling molecules associated with this phenomenon however have not been characterized. In contrast to APCs expressing wild-type class I antigen, cells expressing or3 domain mutant class I antigen fail to stimulate CTL phosphatidyhnositol hydrolysis (25) . Other intracellular changes that may be elicited in CTL upon engagement with the or3 domain mutant class I-peptide complexes have not been described. However, since the mutant molecule-peptide complexes fail to stimulate CTL avidityenhanced CD8 binding, they may provide, by comparison with wild-type class I-peptide complexes, a means to identify CTL transmembrane signaling events resulting in avidity-enhanced CD8 binding.
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